Minidiab

Minidiab

glipizide

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Concise Prescribing Info
Contents
Glipizide
Indications/Uses
Adjunct to diet & exercise to improve glycemic control in adult w/ type 2 DM.
Dosage/Direction for Use
Initially, 5 mg daily. Dose range: 2.5-30 mg daily. Max recommended daily dosage: 40 mg. Elderly & other patient at risk for hypoglycemia May be started on 2.5 mg. Max single dose: 15 mg.
Administration
Should be taken on an empty stomach: Take 30 min before meals.
Contraindications
Hypersensitivity. Type 1 DM, diabetic ketoacidosis & coma.
Special Precautions
Severe hypoglycemia. Patients w/ G6PD-deficiency. Periodically monitor blood glucose & perform HbA1c assessment. May affect ability to drive & use machines. Renal & hepatic impairment. Discontinue 1 mth before expected delivery date in pregnancy. Lactation. Elderly, debilitated or malnourished patients.
Adverse Reactions
Hypoglycaemia; nausea, diarrhea, upper abdominal pain.
Drug Interactions
Increased hypoglycemic effect w/ antifungals, NSAIDs, high-dose salicylates, alcohol, β-blockers, ACE inhibitors, H2-receptor antagonists, MAOIs, quinolones, sulfonamides, chloramphenicol, probenecid & coumarins. Increased t½ w/ fluconazole. Increased plasma levels w/ voriconazole. Elevated blood glucose w/ high-dose phenothiazines, corticosteroids, sympathomimetics, thiazides & other diuretics, thyroid products, estrogens, progestogens, OCs, phenytoin, nicotinic acid, Ca-channel blockers & INH.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BB07 - glipizide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Presentation/Packing
Form
Minidiab tab 5 mg
Packing/Price
160's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in